Project Grant R61HL183016
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $762K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $240,600 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to evaluate the combined immunomodulatory effects of macrolides and corticosteroids in hospitalized patients with community-acquired pneumonia. The study investigates how macrolide antibiotics and corticosteroids, often coadministered in community-acquired pneumonia treatment, affect inflammatory markers and clinical outcomes....
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $593,663 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate thrombolysis resistance in acute ischemic stroke with large vessel occlusion. The project addresses the failure of intravenous thrombolysis with tissue plasminogen activator (TPA) to achieve successful recanalization in most eligible patients. Mayo Clinic will conduct three integrated research activities: define metabolic...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $149,214 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lipid-loaded macrophages in atherosclerotic plaque inflammation. The recipient will characterize the metabolic landscape and cell fate decisions of atheroma-derived macrophages under lipid loading, examining how lipid-associated macrophages release extracellular adenosine triphosphate as a pro-inflammatory signaling...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic Arizona $1,665,204 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how P2RX7-expressing CD4+ T cells control virus-induced lung sequelae. The research defines how severe respiratory infections such as influenza and SARS-CoV-2 promote pathogenic lung CD4+ T cell accumulation that perpetuates long-term lung damage, including the irreversible organ dysfunction observed in long COVID...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $441,100 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research targeting phosphoglucomutase in Pneumocystis pneumonia. The research addresses the glucan-rich cell wall of Pneumocystis, which synthesizes β-glucans from uridine diphosphate glucose, a pathway requiring phosphoglucomutase (PGM) to interconvert glucose-6-phosphate and glucose-1-phosphate. Prior...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $242,100 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate a translational precision-cut lung slice (PCLS) model for testing host-response mechanisms and therapeutic agents in Pneumocystis pneumonia. The project, titled "A Translational Precision-Cut Lung Slice Model for Host-Response and Therapeutic Testing in Pneumocystis Pneumonia,"...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $801,170 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct HOPE: Advancing HFPEF Management Through Evidence-Based Treatment Optimization and Outcome Prediction, a project grant focused on heart failure with preserved ejection fraction. Mayo Clinic will develop therapeutic discovery and biomarker prediction models for HFPEF patients through two integrated research strategies. First, the...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $624,521 on February 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on the regulation of target cell survival by the kinases TBK1 and IKKE in T cell-mediated killing of infected and tumor cells. The research investigates how T cells use interferon-gamma for paracrine killing of target cells, with particular focus on how TBK1 and IKKE regulate susceptibility of B16...
- Federal Grant Award Summary Mayo Clinic received a $783,661 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 5, 2025, with completion scheduled for August 31, 2026. The award funds a pragmatic, randomized clinical trial evaluating the effectiveness and safety of oral midodrine as a vasopressor-sparing agent in patients with sepsis-associated hypotension. The study seeks to reduce intensive...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $820,111 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the cell-specific role of the CD40L-CD40 co-stimulatory dyad in modulating atherosclerosis and natural antibody production. The project examines how CD40 expression on B1 cells—innate B cells that produce atheroprotective anti-oxidation-specific-epitope (OSE) immunoglobulin M—protects against atherosclerosis by...